Our medicines have a profound impact on lives, because everything we do focuses on that goal

Mr. Zarkoski brings 30 years of industry experience in quality, manufacturing, and supply chain roles, developing processes and leading teams at both site and global levels. Over the course of his career, Joseph has also held leadership roles at Wyeth, Merck & Co., Johnson & Johnson, Pfizer, and Shire.

He earned a Bachelor of Science degree in biology from Villanova University.

Dr. Aycardi brings more than 20 years of experience in the pharmaceutical industry and clinical development.

He previously served as Xenon Pharmaceuticals’ Chief Medical Officer. Dr. Aycardi also has held key roles in clinical development, biostatistics, data management, translational medicine and medical research with Teva Pharmaceuticals, EMD Serono, Biogen Idec and Merck & Co.

Dr. Aycardi’s has worked in multiple therapeutic areas throughout his career, but has concentrated heavily in Neurology and conditions of the Central Nervous System.

He received his medical degree in his home country of Colombia, and was a practicing neurologist there prior to joining the pharmaceutical industry.

Mr. Valosky brings more than 24 years of industry experience, including Marketing and Sales leadership roles within Endocrinology, Cardiovascular, Obesity, Neuroscience, Oncology, and Digital Therapeutic fields. He worked for six years in marketing at Eli Lilly, 15 years at Takeda in various roles of increasing responsibility growing brands and sales, and most recently served as Vice President of Sales & Marketing at Pear Therapeutics, where he successfully launched the first FDA-authorized prescription digital therapeutics.

Mr. Valosky earned his Master in Business Administration from Indiana University and his Bachelor of Science in Business Administration from The Ohio State University.

In his spare time, Mr. Valosky serves as a mentor for the Healthcare Businesswomen’s Association, and volunteers with the Knights of Columbus and Canine Companions for Independence.

Mr. Adams is a pricing strategy expert who is future focused with the ability to gather and transform insights into strategy and an established record of driving profitability across multiple therapeutic areas. Previously working for Payer Sciences, Sanofi, and Novo Nordisk, he brings global market access experience in launching products within North America, Europe, and Japan. Expertise in enterprise strategy development, with focus on profit growth through pricing and market access strategies.

He earned his Master of Business Administration from Fox School of Business at Temple University and his Bachelor of Business Administration from Miami University.

Mr. Palko is a strategic pharmaceutical industry commercial executive with significant leadership demonstrated in US and Global Marketing, US Sales, Franchise and Portfolio Strategy, New Product Planning and Business Development, and Advertising Agency Client Management. Currently, Greg is VP, Oncology Franchise Head for the North America Region.

He brings nearly 25 years of oncology experience across both solid and hematologic cancers (eg prostate, lung, ovarian, breast, CRC, CML, CLL, AML, multiple myeloma, and lymphoma) and launching several successful oncology products. He previously served as Commercial Head of Oncology at Imbrium Therapeutics, Head of US Oncology Sales at Sun Pharma, and Global Franchise Head for Hematology at Novartis.

Mr. Palko earned a Pharmacy degree from Rutgers University and a Masters of Business Administration from Fairleigh Dickinson University. He has served as adjunct professor for Fairleigh Dickenson University’s Pharmacy School and has led multiple pharmacy and business student preceptorships during his pharmaceutical career.

Mr. Wilson brings more than 25 years of diversified experience in Sales, Global/US Marketing, Alliance Management, Business Development & Licensing, and General Management.

He previously served as Vice President and Head US Endocrine Franchise at Takeda, where he had full P&L responsibility for the US Endocrine Franchise and general management for all cross-functional activities (Marketing, Sales, Medical, Market Access, Patient Services). He also represented US interests to ensure Global strategic alignment (Global Project Team) and with LCM activities including Business Development & Licensing.

He worked for 3 years at Shire and more than 11 years at Novartis, where after rising through the global ranks, he ultimately served as Executive Director of Global Strategic Alliances and as Business Development and Licensing Executive Director.

He earned his Master of Business Administration from Cornell Johnson Graduate School of Management and his Bachelor of Science in Chemistry from the University of Exeter.

Mr. Morrissey brings more than 20 years experience in commercial operations, analytics, and marketing, with expertise in analytical-based approaches to the marketplace and new product launches. He has successfully led cross-functional teams in strategic initiatives focusing on cost reduction and productivity improvement, resulting in millions of dollars in savings and reduced expenses. He has extensive knowledge of pharmaceutical, medical device, and CPG industries.

Mr. Morrissey earned his Master of Business Administration from the Fordham Gabelli School of Business and his Bachelor's Degree in mass communications from the University at Albany, SUNY.

Hidekuni Kaito has over 20 years of clinical development, project management, business development, and oncology/hemato-oncology expertise both in Japan and the United States. He previously held roles of increasing responsibility at Fujifilm Kyowa Kirin Biologics and Centus Therapeutics. Hide-san received his Bachelor of Science from Saitama University and his Master of Science from the University of Tokyo.